inno glp-1 China's Sciwind sells S. Korea rights of drug to HK Inno.N Inno Shred GLP-1

9 pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2019

Mazdutide vs Tirzepatide vs Semaglutide: Comparative Efficacy Comparative Efficacy of Incretin-Based Therapies After ~48 Weeks This bar chart presents a direct comparison between Mazdutide 6 mg, Tirzepatide 15 mg, Semaglutide 2.4 mg, and Placebo across three key anthropometric outcomes: Percentage Weight Loss Tirzepatide: 15.0% Mazdutide: 14.0% Semaglutide: 12.4% Placebo: +0.3% Patients Achieving 15% Weight Loss Tirzepatide: 51.0% Mazdutide: 49.5% Semaglutide: 36.0% Placebo: 2.0% Reduction in Waist Circumference (cm) Mazdutide: 10.7 cm Tirzepatide: 9.5 cm Semaglutide: 8.5 cm Placebo: 1.4 cm Interpretation Mazdutide demonstrates comparable efficacy to tirzepatide in both absolute weight reduction and waist circumference improvement, outperforming semaglutide across these endpoints

This bindings dynamic nature is intriguing

Una historia de inyecciones y de barreras Desde mediados de los aos 2000, los agonistas del receptor GLP-1 (glucagon-like peptide-1) se han consolidado como una piedra angular en el tratamiento de la diabetes tipo 2

doi: 10.3389/fncel.2021.636176 Received 01 December 2020 Accepted 10 February 2021 Published 08 March 2021 Volume 15 - 2021 Edited by Jose Angel Morales-Garcia, Complutense University of Madrid, Spain Reviewed by Talita Glaser, University of So Paulo, Brazil

Success stories claiming 15+ pounds monthly beyond month one without mentioning dietary restriction or starting BMI above 35 are statistically unlikely and should be evaluated critically